PPBT
Income statement / Annual
Last year (2025), Purple Biotech Ltd's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Purple Biotech Ltd's net income was -$26.39 M.
See Purple Biotech Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.00 M |
$1.00 M |
$100.00 K |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$236.65 K
|
$80.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$236.65 K
|
$999.92 K
|
$1.00 M
|
$100.00 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$3.73 M
|
$7.62 M
|
$17.03 M
|
$16.32 M
|
$11.83 M
|
$7.29 M
|
$2.28 M
|
$5.27 M
|
$4.64 M
|
$4.18 M
|
| General & Administrative Expenses |
$2.98 M
|
$2.94 M
|
$4.84 M
|
$5.96 M
|
$5.82 M
|
$0.00
|
$6.08 M
|
$5.19 M
|
$6.39 M
|
$3.00 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.98 M
|
$2.94 M
|
$4.84 M
|
$5.96 M
|
$5.82 M
|
$5.81 M
|
$6.08 M
|
$5.19 M
|
$6.39 M
|
$3.00 M
|
| Other Expenses |
$20.74 M
|
$450.00 K
|
$393.00 K
|
$321.00 K
|
$286.00 K
|
$1.00
|
$356.00 K
|
$0.00
|
$1.03 M
|
$0.00
|
| Operating Expenses |
$27.46 M
|
$11.01 M
|
$22.27 M
|
$22.60 M
|
$17.93 M
|
$13.10 M
|
$8.75 M
|
$8.83 M
|
$12.06 M
|
$7.18 M
|
| Cost And Expenses |
$27.46 M
|
$11.01 M
|
$22.27 M
|
$22.60 M
|
$17.93 M
|
$13.33 M
|
$8.75 M
|
$8.83 M
|
$12.06 M
|
$7.18 M
|
| Interest Income |
$227.00 K
|
$260.00 K
|
$474.00 K
|
$532.00 K
|
$320.00 K
|
$255.78 K
|
$151.00 K
|
$93.00 K
|
$106.00 K
|
$138.00 K
|
| Interest Expense |
$39.00 K
|
$41.00 K
|
$56.00 K
|
$67.00 K
|
$79.00 K
|
$56.39 K
|
$181.00 K
|
$9.00 K
|
$26.00 K
|
$6.00 K
|
| Depreciation & Amortization |
$203.00 K
|
$186.00 K
|
$197.00 K
|
$201.00 K
|
$231.00 K
|
$235.00 K
|
$179.00 K
|
$7.00 K
|
$4.00 K
|
$2.00 K
|
| EBITDA |
-$26.25 M |
-$7.05 M |
-$19.72 M |
-$21.49 M |
-$17.52 M |
-$13.10 M |
-$6.14 M |
-$5.55 M |
-$12.88 M |
-$7.04 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-6.14
|
-5.55
|
-128.83
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-7.16
|
-7.83
|
-119.66
|
0
|
| Total Other Income/Expenses Net |
$966.00 K
|
$3.73 M
|
$2.29 M
|
$843.00 K
|
$108.00 K
|
-$15.57 M
|
$1.48 M
|
$2.26 M
|
-$1.04 M
|
-$4.94 M
|
| Income Before Tax |
-$26.49 M
|
-$7.28 M
|
-$19.98 M
|
-$21.76 M
|
-$17.83 M
|
-$28.90 M
|
-$5.89 M
|
-$5.57 M
|
-$12.91 M
|
-$12.13 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-5.89
|
-5.57
|
-129.13
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$216.00 K
|
$0.00
|
$0.00
|
$6.00 K
|
| Net Income |
-$26.39 M
|
-$7.24 M
|
-$19.88 M
|
-$21.67 M
|
-$18.38 M
|
-$28.20 M
|
-$5.85 M
|
-$5.20 M
|
-$12.18 M
|
-$12.13 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
-5.85
|
-5.2
|
-121.77
|
0
|
| EPS |
-5.5 |
-4.42 |
-17.96 |
-24 |
-20 |
-50 |
-56 |
-74 |
-258 |
-422 |
| EPS Diluted |
-5.5 |
-4.42 |
-17.96 |
-24 |
-20 |
-50 |
-56 |
-74 |
-258 |
-422 |
| Weighted Average Shares Out |
$4.80 M
|
$1.64 M
|
$1.11 M
|
$902.83 K
|
$910.19 K
|
$562.41 K
|
$105.59 K
|
$71.03 K
|
$47.28 K
|
$28.78 K
|
| Weighted Average Shares Out Diluted |
$4.80 M
|
$1.64 M
|
$1.11 M
|
$904.05 K
|
$878.40 K
|
$575.01 K
|
$96.84 K
|
$71.03 K
|
$47.28 K
|
$28.78 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
